Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 1, 2013, Pages 123-136

  Comi, Giancarlo ^a   Hartung, Hans Peter ^b   Kurukulasuriya, Nuwan C ^c   Greenberg, Steven J ^c   Scaramozza, Matthew ^d  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MERCK SERONO S A   (Switzerland)

^d EMD SERONO INC   (United States)

Author keywords

Cladribine tablets; CLARITY study; Multiple sclerosis; Oral therapy; Risk benefit

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; LAQUINIMOD; PLACEBO; TERIFLUNOMIDE;

CANCER INCIDENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHORIOCARCINOMA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; HAIRY CELL LEUKEMIA; HERPES ZOSTER OTICUS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOMA; MELANOMA; MULTIPLE SCLEROSIS; NAUSEA; OVARY CARCINOMA; PANCREAS CARCINOMA; PANCYTOPENIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREGNANCY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; SPONTANEOUS ABORTION; THERAPEUTIC ABORTION; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; UTERINE CERVIX CARCINOMA IN SITU; UTERUS MYOMA; VOMITING;

ADMINISTRATION, ORAL; CLADRIBINE; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SAFETY-BASED DRUG WITHDRAWALS; TABLETS;

EID: 84871586750     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.754012     Document Type: Review

References (84)

1. National Multiple Sclerosis Society. About MS. Available from: http://www. nationalmssociety.org/about-multiplesclerosis/what-we-know-about-ms/ faqsabout-ms/index.aspx [Last accessed 21 September 2012]
2. World Health Organization, Multiple Sclerosis International Federation. Atlas of multiple sclerosis. Available from: http://www.atlasofms.org/query.aspx
3. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007;61:1922-30 (Pubitemid 47573097)
4. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74:2004-15
5. Heard RN. The spectrum of multiple sclerosis. Curr Allergy Asthma Rep 2007;7:280-4 (Pubitemid 46958745)
6. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94 (Pubitemid 26100751)
8. PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
9. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol 2005;252:8-13 (Pubitemid 40179012)
10. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
11. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
12. Barkhof F, Polman CH, Radue EW, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 2007;64:1292-8 (Pubitemid 47403084)
13. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-4 (Pubitemid 37025380)
14. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50 (Pubitemid 40259974)
15. Daugherty KK, Butler JS, Mattingly M, Ryan M. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc (2003) 2005;45:371-5
16. Morrissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005;12:74-87 (Pubitemid 41712024)
17. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
18. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
19. Coyle PK. Potential clinical place of emerging therapies. Int J MS Care 2007;9:27-9
20. Merck Serono. Press Release, July 12, 2010: Merck Serono's cladribine tablets FOR MS approved in Russia. Available from: http://www.merckserono.com/ corp. merckserono/en/images/20100712-en-tcm112-55022.pdf [Last accessed 21 September 2012]
21. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26
22. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9
23. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2012;365:1293-303
24. Fox R, Miller D, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
25. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5¢-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993;81:597-601 (Pubitemid 23040848)
26. Laugel B, Challier J, Siegfried C, et al. The mechanism of action behind the lymphocyte-depleting and immunomodulatory effect of cladribine. Annual Meeting of the American Academy of Neurology [AAN], Seattle, USA, 25 April-2 May 2009. Abstract P01.108. Neurology 2009;72:A35
27. Salvat C, Curchod M-L, Guedj E, et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Dusseldorf, Germany, 9-12 September 2009. Abstract P280. Mult Scler 2009;15(Suppl 2):S74-5
28. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996;93:1716-20 (Pubitemid 26075191)
29. Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005;5:721-7 (Pubitemid 41679640)
30. Hartung HP, Aktas O, Kieseier B, et al. Development of oral cladribine for the treatment of multiple sclerosis. J Neurol 2010;257:163-70
31. Australian Government, Department of Health and Aging, Therapeutic Goods Administration. Australian Public Assessment Report for Cladribine Tablets. 2011. Available from: http://www.tga.gov.au/pdf/auspar/ausparmovectro. pdf [Last accessed 21 September 2012]
32. Liliemark J. The clinical pharmacokinetics of cladribine. Clinical Pharmacokinet 1997;32:120-31 (Pubitemid 27104411)
33. Kopadze T, Dobert M, Leussink VI, et al. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol 2009;16:409-12
34. Cannella B, Cross AH, Raine CS. Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J Exp Med 1990;172:1521-4 (Pubitemid 20366230)
35. Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, Belniak E. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand 2010;122:409-13
36. Laugel B, Borlat F, Galibert L, et al. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. J Neuroimmunol 2011;240-241:52-7
37. Dressel A, Korsen M, Alonso SB, et al. Long-term immunomodulatory effects of cladribine in vitro: predominant induction of TH2 type cytokines [Poster P02.191]. Annual Meeting of the American Academy of Neurology [AAN]; 9-16 April 2011; Honolulu, Hawaii
38. Sipe JC. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Rev Neurother 2010;10:365-75
39. Guarnaccia JB, Rinder H, Smith B. Preferential depletion of lymphocyte subpopulations by cladribine in a phase III clinical trial in multiple sclerosis. World Congress on Treatment and Research in Multiple Sclerosis [WCTRIMS], 17-20 September 2008, Montreal, Canada. Abstract P55. Mult Scler 2008;14:S45
40. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54:1145-55 (Pubitemid 30151860)
41. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994;120:784-91 (Pubitemid 24125300)
42. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983;62:737-43 (Pubitemid 13008659)
43. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci USA 1977;74:5677-81
44. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992;340:952-6
45. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26 (Pubitemid 28446680)
46. Zinzani PL. Non-Hodgkin's lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol 2002;15:505-16
47. Huynh E, Sigal D, Saven A. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Leuk Lymphoma 2009;50:12-17
48. Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 2010;116:2884-96
49. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007;23:2667-76 (Pubitemid 350146405)
50. Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999;111:35-44 (Pubitemid 29047108)
51. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13 (Pubitemid 24199417)
52. Beutler E, Sipe J, Romine J, et al. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996;33:45-52 (Pubitemid 26061753)
53. Sipe J, Gardner J, Beutler E. The efficacy of cladribine in relapsing-remitting multiple sclerosis: clinical data from a randomised, double-blind, 18-month, phase II trial. American Academy of Neurology [AAN], Chicago, Illinois, USA, 12-19 April, 2008. Abstract P02.160. Neurology 2008;70:A91
54. Stelmasiak Z, Solski J, Nowicki J, et al. Effect of parenteral cladribine on relapse rates in patients with relapsing-remitting multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult Scler 2009;15:767-70
55. Cook S, Gardner JD, Greenberg S. For the Cladribine Clinical Study Group. A combined analysis of data from four randomized, double-blind, placebo-controlled trials of parenteral cladribine and one open-label pilot study to assess the safety and tolerability profile of repeated periods of cladribine treatment in patients with progressive or relapsing multiple sclerosis [Poster P02.180]. 60th Annual Meeting of the American Academy of Neurology [AAN]; 12-19 April 2008; Chicago, Illinois, USA
56. Stelmasiak Z, Bartosik-Psujek H, Belniak-Legiec E, Mitosek-Szewczyk K. The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS). Ann Univ Mariae Curie Sklodowska Med 2000;55:221-5
57. Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011;10:329-37
58. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-60
59. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 2011;7:332-42
60. Amato MP, Portaccio E. Management options in multiple sclerosis-associated fatigue. Expert Opin Pharmacother 2012;13:207-16
61. Rammohan K, Comi G, Cook S, et al. Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study. Annual Meeting of the European Neurological Society [ENS]; 28-31 May 2011; Lisbon, Portugal. Oral presentation O208
62. Cook S, Comi G, Giovannoni G, et al. Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study [Poster P905]. Annual Meeting of the European Neurological Society [ENS]; 28-31 May 2011; Lisbon, Portugal
63. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011;17:578-93
64. European Medicines Agency (EMA). Withdrawal assessment report for Movectro. 2011. Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Application-withdrawal-assessment-report/2011/03/WC500104393.pdf [Last accessed 21 September 2012]
65. Miret M, Bock D, Bischof D. Analysis of the risk of malignancies in patients with multiple sclerosis treated with cladribine in completed and ongoing clinical studies [Poster P890]. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS]; 19-22 October 2011; Amsterdam, Netherlands
66. European Medicines Agency (EMA). Gilenya: European Public Assessment Report. 2011. Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/002202/human-med-001433. jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d124 [Last accessed 21 September 2012]
67. O'Connor P, Wolinsky J, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;3:1293-303
68. Merck Serono. Press Release, June 22, 2011: Merck Serono: Regulatory Update on Cladribine Tablets. Available from: http://www.merckserono.com/corp. merckserono-2011/en/images/20110622-en-tcm1494-76074.pdf [Last accessed 21 September 2012]
69. Viglietta V, Miret M, Greenberg S, et al. Development and long-term safety evaluation of cladribine tablets as a short-course, oral therapy for relapsing and early forms of multiple sclerosis: ongoing clinical trials [Poster P1410]. Annual Meeting of the European Federation of Neurological Societies [EFNS]; 25-28 September 2010; Geneva, Switzerland
70. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305-14 (Pubitemid 33019542)
71. Kahl LE. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 1994;21:84-6 (Pubitemid 24044923)
72. Moutsopoulos HM, Gallagher JD, Decker JL, Steinberg AD. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum 1978;21:798-802 (Pubitemid 9126666)
73. Manzi S, Kuller LH, Kutzer J, et al. Herpes zoster in systemic lupus erythematosus. J Rheumatol 1995;22:1254-8
74. Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991;90:295-8
75. Engels EA, Rosenberg PS, Biggar RJ. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study. J Infect Dis 1999;180:1784-9
76. Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995;9:1153-8
77. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-6
78. Montalban X, Cohen BA, Jeffrey DR, et al. Oral cladribine added to interferon beta-1a for active multiple sclerosis: a 96-week, double-blind, placebo-controlled phase IIB study [Poster P809]. The 23rd Congress of the European Committee for Research and Treatment in Multiple Sclerosis [ECTRIMS]; 11-14 October 2007; Prague, Czech Republic
79. Coyle PK, Leist T, Comi G, et al. Study design of the ORACLE MS study: cladribine tablets in early multiple sclerosis [Poster W31]. Consortium of Multiple Sclerosis Centers [CMSC]; 27-30 May 2009; Atlanta, USA
80. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
81. European Medicines Agency (EMA). Gilenya SPC. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002202/WC500104528.pdf [Last accessed 21 September 2012]
82. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-78
83. Giovannoni G, Gold R, Selmaj K, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial [abstract 149]. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; 19-22 October 2011; Amsterdam, The Netherlands
84. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 2011;34:28-35